About us Contacts Drug interactions: 390 212
Drug search by name

Adempas Tablets and Kaletra

Determining the interaction of Adempas Tablets and Kaletra and the possibility of their joint administration.

Check result:
Adempas Tablets <> Kaletra
Relevance: 14.05.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Ritonavir may significantly increase the blood levels of riociguat. You may be more likely to experience serious side effects such as low blood pressure and bleeding. The risk of other side effects such as dizziness, lightheadedness, fainting, headache, flushing, palpitation, nasal congestion, upset stomach, and constipation may also increase. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

ADJUST DOSE: Coadministration with drugs that are both potent multi-pathway CYP450 and P-glycoprotein/breast cancer resistant protein (P-gp/BCRP) inhibitors may significantly increase the plasma concentrations of riociguat, which is primarily metabolized by CYP450 1A1, 3A, 2C8 and 2J2, and also a substrate of the P-gp/BCRP efflux transporter. Increased levels of riociguat may increase the risk for hypotension. According to the product labeling, administration of riociguat with the potent CYP450 and P-gp/BCRP inhibitor ketoconazole resulted in increases of riociguat peak plasma concentration (Cmax) and systemic exposure (AUC) by approximately 1.5- and 2.5-fold, respectively. The Cmax and AUC of the active metabolite, M1, which has 1/3 to 1/10 the pharmacologic activity of riociguat, were reduced by approximately 50% and 25%, respectively.

MANAGEMENT: Caution is advised if riociguat is prescribed in combination with potent, dual multi-pathway CYP450 and P-gp/BCRP inhibitors such as itraconazole, ketoconazole, and some HIV protease inhibitors. A starting dosage of 0.5 mg three times a day should be considered, and patients should be monitored for signs and symptoms of hypotension.

References
  • "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Adempas Tablets

Generic Name: riociguat

Brand name: Adempas

Synonyms: Riociguat

Kaletra

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction